Inventor · disambiguated record
Cécile Schiffer-Mannioui
Also filed as: SCHIFFER-MANNIOUI CECILE · SCHIFFER-MANNIOUI CÉCILE
11 granted patents·9 pending applications·42 citations·filing 2008–2023
88Inventor score
Top patents by PatentIndex Score
20 records- 0196US11077144B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted Aug 3, 2021·7 cites·17 claims
- 0294US10874693B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2014·Granted Dec 29, 2020·7 cites·11 claims
- 0393US10752684B2ROR1 (NTRKR1) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Aug 25, 2020·12 cites·10 claims
- 0491US10759868B2Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2015·Granted Sep 1, 2020·6 cites·8 claims
- 0588US11690873B2Universal chimeric antigen receptor T cells specific for CD22CELLECTIS SA·Filed 2018·Granted Jul 4, 2023·4 cites·20 claims
- 0687US11304975B2Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 19, 2022·4 cites·6 claims
- 0777US11311575B2Methods for engineering highly active T cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 26, 2022·1 cites·15 claims
- 0877US11007224B2CD19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2020·Granted May 18, 2021·0 cites·10 claims
- 0973US2024269178A1Cd19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2023·Application pending·0 cites
- 1070US2023201260A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 1167US2023050345A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 1265US11987639B2Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2020·Granted May 21, 2024·0 cites·16 claims
- 1365US10544201B2ROR1 specific multi-chain chimeric antigen receptorCELLECTIS·Filed 2015·Granted Jan 28, 2020·1 cites·20 claims
- 1460US2023056268A1Methods for engineering highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 1557US2021000869A9Cd19 specific chimeric antigen receptor and uses thereofCELLECTIS·Filed 2019·Application pending·0 cites
- 1654US2023068949A1New mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapyCELLECTIS·Filed 2020·Application pending·0 cites
- 1745US2010284973A1Use of a L. Casei Strain For the Preparation of a Composition for Inhibiting Mast Cell ActivationSCHIFFER-MANNIOUI CECILE·Filed 2008·Application pending·0 cites
- 1844US10752670B2Anti-GD3 specific chimeric antigen receptors for cancer immunotherapyCELLECTIS·Filed 2016·Granted Aug 25, 2020·0 cites·12 claims
- 1942US2010028263A1Methods for inhibiting mast cell activation and treating mast cell-dependent inflammatory diseases and disorders using lactobacillusPASTEUR INSTITUT·Filed 2009·Application pending·0 cites
- 2037US2017275366A1EGFRvIII Specific Chimeric Antigen Receptor For Cancer ImmunotherapyPFIZER·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cécile Schiffer-Mannioui files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →